Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Net Income Loss of -$412.78 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -161.3% in Net Income Loss from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$12.38 million | Q1 2014: -$12.25 million | Q2 2014: -$18.30 million | Q3 2014: $3.70 million | Q4 2014: -$26.66 million | Q1 2015: -$4.96 million | Q2 2015: -$31.90 million | Q3 2015: -$40.26 million | Q1 2016: -$23.20 million | Q2 2016: -$55.95 million | Q3 2016: -$62.83 million | Q4 2016: -$23.20 million | Q1 2017: -$66.17 million | Q2 2017: -$83.08 million | Q3 2017: -$77.14 million | Q1 2018: -$90.83 million | Q2 2018: -$68.75 million | Q3 2018: -$94.66 million | Q1 2019: -$93.08 million | Q2 2019: -$109.87 million | Q3 2019: -$106.17 million | Q1 2020: -$40.26 million | Q2 2020: -$90.48 million | Q3 2020: -$98.98 million | Q1 2021: $1.87 billion | Q2 2021: -$86.22 million | Q3 2021: -$88.77 million | Q1 2022: -$94.77 million | Q2 2022: -$91.81 million | Q3 2022: -$81.75 million | Q1 2023: -$81.02 million | Q2 2023: -$83.81 million | Q3 2023: -$91.32 million | Q1 2024: -$81.55 million | Q2 2024: -$96.12 million | Q3 2024: $947.92 million | Q1 2025: -$89.29 million | Q2 2025: -$112.02 million | Q3 2025: -$103.43 million.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Net Income Loss has declined by 1,641.3%.
- Historical annual values: Fiscal year 2025: -$412.78 million | Fiscal year 2024: $673.73 million | Fiscal year 2023: -$352.09 million | Fiscal year 2022: -$231.80 million | Fiscal year 2021: $1.60 billion | Fiscal year 2020: -$327.37 million | Fiscal year 2019: -$411.47 million | Fiscal year 2018: -$346.03 million | Fiscal year 2017: -$314.67 million | Fiscal year 2016: -$198.47 million | Fiscal year 2015: -$117.73 million | Fiscal year 2014: -$53.50 million | Fiscal year 2013: -$39.41 million | Fiscal year 2012: -$20.10 million | Fiscal year 2011: -$23.71 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: